344 related articles for article (PubMed ID: 29311117)
21. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
22. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
23. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
[TBL] [Abstract][Full Text] [Related]
25. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
26. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
[TBL] [Abstract][Full Text] [Related]
27. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW
BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240
[TBL] [Abstract][Full Text] [Related]
28. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
30. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
31. Molecular biomarker analyses using circulating tumor cells.
Punnoose EA; Atwal SK; Spoerke JM; Savage H; Pandita A; Yeh RF; Pirzkall A; Fine BM; Amler LC; Chen DS; Lackner MR
PLoS One; 2010 Sep; 5(9):e12517. PubMed ID: 20838621
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
33. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques.
Brouwer A; De Laere B; van Dam PJ; Peeters D; Van Haver J; Sluydts E; El Moussaoui A; Mendelaar P; Kraan J; Peeters M; Van Laere S; Dirix L
PLoS One; 2019; 14(9):e0220906. PubMed ID: 31483799
[TBL] [Abstract][Full Text] [Related]
34. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
[TBL] [Abstract][Full Text] [Related]
36. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
37. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer.
Strati A; Zavridou M; Kallergi G; Politaki E; Kuske A; Gorges TM; Riethdorf S; Joosse SA; Koch C; Bohnen AL; Mueller V; Koutsodontis G; Kontopodis E; Poulakaki N; Psyrri A; Mavroudis D; Georgoulias V; Pantel K; Lianidou ES
Clin Chem; 2021 Oct; 67(10):1395-1405. PubMed ID: 34322698
[TBL] [Abstract][Full Text] [Related]
38. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
39. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]